IP Library › Patent Application 11051411
Patent Application
App. No. 11/051,411

Inducing cellular immune responses to p53 using peptide and nucleic acid compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/051,411
Abstract

This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare p53 epitopes, and to develop epitope-based vaccines directed towards p53-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and treatment of cancer.

Claims (57)

1 - 40 . (canceled)

41 . An isolated peptide less than 15 amino acids in length comprising an oligopeptide selected from the group consisting of:

ALNKMFBQV

(SEQ ID NO:1241)

ALNKMFCQLAK

(SEQ ID NO:191)

APAAPTPAAPA

(SEQ ID NO:362)

BLLAKTBPV

(SEQ ID NO:1251)

BLTIHYNYV

(SEQ ID NO:1264)

BQLAKTBPV

(SEQ ID NO:1250)

CLLAKTCPV

(SEQ ID NO:1425)

GTRVRAMAIYK

(SEQ ID NO:211)

KLBPVQLWV

(SEQ ID NO:1254)

KLSQHMTEV

(SEQ ID NO:1259)

KLYQGSYGFRV

(SEQ ID NO:1414)

RLPEAAPPV

(SEQ ID NO:1229)

and

SLPPPGTRV.

(SEQ ID NO:1257)

42 . The peptide of claim 41 , wherein said oligopeptide is ALNKMFBQV (SEQ ID NO:1241).

43 . The peptide of claim 41 , wherein said oligopeptide is ALNKMFCQLAK (SEQ ID NO:191).

44 . The peptide of claim 41 , wherein said oligopeptide is APAAPTPAAPA (SEQ ID NO:362).

45 . The peptide of claim 41 , wherein said oligopeptide is BLLAKTBPV (SEQ ID NO:1251).

46 . The peptide of claim 41 , wherein said oligopeptide is BLTIHYNYV (SEQ ID NO:1264).

47 . The peptide of claim 41 , wherein said oligopeptide is BQLAKTBPV (SEQ ID NO:1250).

48 . The peptide of claim 41 , wherein said oligopeptide is CLLAKTCPV (SEQ ID NO:1425).

49 . The peptide of claim 41 , wherein said oligopeptide is GTRVRAMAIYK (SEQ ID NO:211).

50 . The peptide of claim 41 , wherein said oligopeptide is KLBPVQLWV (SEQ ID NO:1254).

51 . The peptide of claim 41 , wherein said oligopeptide is KLSQHMTEV (SEQ ID NO:1259).

52 . The peptide of claim 41 , wherein said oligopeptide is KLYQGSYGFRV (SEQ ID NO:1414).

53 . The peptide of claim 41 , wherein said oligopeptide is RLPEAAPPV (SEQ ID NO:1229).

54 . The peptide of claim 41 , wherein said oligopeptide is SLPPPGTRV (SEQ ID NO:1257).

55 . The peptide of claim 41 , which is linked to a T helper peptide.

56 . The peptide of claim 41 , which is linked to spacer or linker amino acids.

57 . The peptide of claim 41 , which is linked to a carrier.

58 . The peptide of claim 41 , which is linked to a lipid.

59 . A linked protein comprising the peptide of claim 41 .

60 . A homopolymer of the peptide of claim 41 .

61 . A heteropolymer of the peptide of claim 41 , and different peptides.

62 . A composition comprising the peptide of claim 41 and a carrier.

63 . A composition comprising the peptide of claim 41 and a pharmaceutically acceptable carrier.

64 . A composition comprising the peptide of claim 41 and a liposome.

65 . A composition comprising the peptide of claim 41 , and one or more different peptides.

66 . The composition of claim 65 , wherein said peptides form a linked polypeptide.

67 . The composition of claim 65 , which comprises a carrier.

68 . The composition of claim 65 further comprising a pharmaceutically acceptable carrier.

69 . The composition of claim 65 , wherein said peptides are linked by spacer or linker amino acids.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: IDM PHARMA, INC.
To: BIOTECH SYNERGY, INC.
Reel/Frame 033453/0170 →